VKTX Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 19%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Biogen, Inc.'s return on equity of 9.36%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 221.59%. On the other hand Biogen, Inc. has an analysts' consensus of $193.00 which suggests that it could grow by 7.29%. Given that Viking Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Biogen, Inc..

Viking Therapeutics, Inc. has a beta of 0.710, which suggesting that the stock is 28.988% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 2.72x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 31.72%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Eli Lilly & Co.'s return on equity of 106.26%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 221.59%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,146.30 which suggests that it could grow by 9.33%. Given that Viking Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Viking Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Viking Therapeutics, Inc. has a beta of 0.710, which suggesting that the stock is 28.988% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 15.91x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 21.32%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Pfizer Inc.'s return on equity of 10.84%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 221.59%. On the other hand Pfizer Inc. has an analysts' consensus of $28.82 which suggests that it could grow by 8.86%. Given that Viking Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Pfizer Inc..

Viking Therapeutics, Inc. has a beta of 0.710, which suggesting that the stock is 28.988% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.51% to investors and pays a quarterly dividend of $0.43 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 2.40x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 21.74%. Viking Therapeutics, Inc.'s return on equity of -28.62% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Viking Therapeutics, Inc. has a consensus price target of $93.39, signalling upside risk potential of 221.59%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $846.85 which suggests that it could grow by 12.75%. Given that Viking Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Viking Therapeutics, Inc. has a beta of 0.710, which suggesting that the stock is 28.988% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Viking Therapeutics, Inc.'s net income of -$90.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.